Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 10/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 5/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19096981 | 1.00 | DGAT1 (0.41) | DGAT1CPS1ACVR1WDR5RPS6KB1 | |
| SCHEMBL20954152 | 0.85 | CPS1 (0.44) | CPS1CHRM2 | |
| SCHEMBL19096982 | 0.85 | CPS1 (0.44) | CPS1CHRM2 | |
| SCHEMBL17375398 | 0.84 | CHRM2 (0.43) | CPS1WDR5RPS6KB1CHRM2 | |
| SCHEMBL19096975 | 0.84 | CHRM2 (0.43) | CPS1WDR5RPS6KB1CHRM2 | |
| SCHEMBL22048387 | 0.83 | NR1H2 (0.46) | DGAT1CPS1RPS6KB1 | |
| SCHEMBL19097001 | 0.82 | SIK1 (0.42) | CPS1ACVR1PARP15PARP10CHRM2 | |
| SCHEMBL19096993 | 0.82 | SIK1 (0.42) | CPS1ACVR1PARP15PARP10CHRM2 | |
| SCHEMBL17385246 | 0.81 | HTR2C (0.51) | CHRM2 | |
| SCHEMBL20976839 | 0.81 | HTR2C (0.51) | CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | DGAT1 4812/4885CPS1 2951/4885ACVR1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.